f8k_061713.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
______________________

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
_______________________
Date of Report:  June 14, 2013  (Date of earliest event reported)

 
 
CAPSTONE THERAPEUTICS CORP.
  
 
(Exact name of registrant as specified in its charter)
  
 

Delaware
  
000-21214
  
86-0585310
(State or other jurisdiction of
 incorporation)
  
(Commission File Number)
  
(I.R.S. Employer
Identification No.)

 
1275 West Washington Street, Suite 101, Tempe, Arizona
   85281
(Address of principal executive offices)    (Zip Code)
 
Registrant’s telephone number, including area code:
(602) 286-5520
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
Section 5 - Corporate Governance and Management
 
Item 5.07.  Submission of Matters to a Vote of Security Holders.
 
 Annual Meeting of Stockholders
 
(a)        Our Annual Meeting of Stockholders was held on June 14, 2013 with a quorum in attendance.
 
(b)        At the Annual Meeting, stockholders elected our nominee for Class I Director and ratified the appointment of Moss Adams LLP as our independent registered public accounting firm for the fiscal year ended December 31, 2013.  The certified results of the matters voted upon at the meeting, which are more fully described in our Proxy Statement, are as follows:
 
Proposal 1: Proposal to Elect a Class I Director For Term Expiring in Year 2016:
 
Number of Shares
 
Nominee Name
 
FOR
WITHHELD
BROKER NON-VOTES
Fredric J. Feldman
 
17,542,354
820,882
11,243,712

 
Proposal 2: Proposal to Ratify the Appointment of Moss Adams LLP as our Independent Registered Public Accounting Firm for Fiscal Year 2013
 
 
Number of Shares
  
 
FOR
AGAINST
ABSTAIN
  
 
 
28,882,384
 
682,686
 
41,878
  

 
  Proposal 3: Advisory Vote on Executive Compensation
 
Number of Shares
 
FOR
 
AGAINST
ABSTAIN
BROKER NON-VOTES
17,419,465
 
746,624
197,147
11,243,712

 
  Proposal 4:  Advisory Vote on Frequency of Holding Future Votes on Executive Compensation:
 
Number of Shares
 
ONE YEAR
TWO YEARS
THREE YEARS
ABSTAIN
BROKER
NON-VOTES
 
4,141,943
 
376,705
13,593,496
251,092
11,243,712
 
 
 
(c)
None
 
(d) 
On June 14, 2013, the Board of Directors of Capstone Therapeutics Corp. (the “Company”) adopted a resolution calling for an advisory vote on Executive Compensation every three years.  The next scheduled Advisory Vote on Executive Compensation will be at the Company’s 2016 Annual Meeting of Stockholders.
 

 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

Dated:  June 17, 2013
  
CAPSTONE THERAPEUTICS CORP.
     
     
     
   
/s/ John M. Holliman, III
   
John M. Holliman, III
   
Executive Chairman